MeiraGTx Holdings plc (MGTX) stock
MGTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 13/3065% below fair value
$8.46−0.28 (-3.20%)
Close on Nov 17, 2026Market cap $812.52MP/E 11.9Yield –
MeiraGTx r&d expenses
Research and development expenses are spending on new products and technology.
MeiraGTx's R&D Expenses for the twelve months ending Jun 30, 2026 was $153.16M, up 31.5% year over year. For fiscal 2025 it was $129.62M, up 8.5% from the year before. The highest annual figure on record is $129.62M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $129.62M | +8.5% |
| FY2024 | Dec 31, 2024 | $119.48M | +15.1% |
| FY2023 | Dec 31, 2023 | $103.79M | +21.1% |
| FY2022 | Dec 31, 2022 | $85.73M | +28.5% |
| FY2021 | Dec 31, 2021 | $66.69M | +96.7% |
| FY2020 | Dec 31, 2020 | $33.91M | +36.3% |
| FY2019 | Dec 31, 2019 | $24.88M | -26.0% |
| FY2018 | Dec 31, 2018 | $33.62M | +50.4% |
| FY2017 | Dec 31, 2017 | $22.36M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $57.83M | +72.7% |
| Q1 FY2026 | Mar 31, 2026 | $31.98M | -2.4% |
| Q4 FY2025 | Dec 31, 2025 | $30.81M | +28.5% |
| Q3 FY2025 | Sep 30, 2025 | $32.53M | +24.0% |
| Q2 FY2025 | Jun 30, 2025 | $33.50M | -4.1% |
| Q1 FY2025 | Mar 31, 2025 | $32.78M | -4.5% |
| Q4 FY2024 | Dec 31, 2024 | $23.99M | -28.8% |
| Q3 FY2024 | Sep 30, 2024 | $26.24M | -5.8% |
| Q2 FY2024 | Jun 30, 2024 | $34.93M | +75.2% |
| Q1 FY2024 | Mar 31, 2024 | $34.32M | +53.8% |
| Q4 FY2023 | Dec 31, 2023 | $33.67M | +54.7% |
| Q3 FY2023 | Sep 30, 2023 | $27.86M | +65.2% |
| Q2 FY2023 | Jun 30, 2023 | $19.94M | -16.9% |
| Q1 FY2023 | Mar 31, 2023 | $22.32M | -3.4% |
| Q4 FY2022 | Dec 31, 2022 | $21.77M | +65.1% |
| Q3 FY2022 | Sep 30, 2022 | $16.86M | -22.0% |
| Q2 FY2022 | Jun 30, 2022 | $24.00M | +58.0% |
| Q1 FY2022 | Mar 31, 2022 | $23.10M | +38.2% |
| Q4 FY2021 | Dec 31, 2021 | $13.18M | +163.7% |
| Q3 FY2021 | Sep 30, 2021 | $21.61M | +367.2% |
| Q2 FY2021 | Jun 30, 2021 | $15.19M | -6.2% |
| Q1 FY2021 | Mar 31, 2021 | $16.71M | +106.7% |
| Q4 FY2020 | Dec 31, 2020 | $5.00M | +8.3% |
| Q3 FY2020 | Sep 30, 2020 | $4.63M | -52.7% |
| Q2 FY2020 | Jun 30, 2020 | $16.20M | +24.9% |
| Q1 FY2020 | Mar 31, 2020 | $8.08M | -25.1% |
| Q3 FY2019 | Sep 30, 2019 | $4.61M | -43.1% |
| Q2 FY2019 | Jun 30, 2019 | $9.77M | +25.4% |
| Q1 FY2019 | Mar 31, 2019 | $12.98M | +87.3% |
| Q4 FY2018 | Dec 31, 2018 | $10.79M | +86.6% |
| Q3 FY2018 | Sep 30, 2018 | $8.11M | +26.9% |
| Q2 FY2018 | Jun 30, 2018 | $7.79M | +45.3% |
| Q1 FY2018 | Mar 31, 2018 | $6.93M | – |
| Q4 FY2017 | Dec 31, 2017 | $5.78M | – |
| Q3 FY2017 | Sep 30, 2017 | $6.39M | – |
| Q2 FY2017 | Jun 30, 2017 | $5.36M | – |
See a number that looks wrong?